Alembic Pharma gains on getting USFDA`s nod for Triamcinolone Acetonide Injectable Suspension
Alembic Pharmaceuticals is currently trading at Rs. 947.55, up by 10.05 points or 1.07% from its previous closing of Rs. 937.50 on the BSE.
The scrip opened at Rs. 984.95 and has touched a high and low of Rs. 984.95 and Rs. 941.90 respectively. So far 383 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1186.00 on 21-Oct-2024 and a 52 week low of Rs. 725.60 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 984.95 and Rs. 911.25 respectively. The current market cap of the company is Rs. 18646.96 crore.
The promoters holding in the company stood at 69.74%, while Institutions and Non-Institutions held 20.35% and 9.92% respectively.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL Single-Dose Vials, 200 mg/5 mL and 400 mg/10 mL (40 mg/mL) Multiple-Dose Vials. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Kenalog-40 Injectable Suspension, of Bristol-Myers Squibb Company.
The company has a cumulative total of 227 ANDA approvals (206 final approvals and 21 tentative approvals) from USFDA. Triamcinolone Acetonide Injectable Suspension USP is indicated for various autoimmune, inflammatory, and other conditions where oral therapy is not feasible.
Alembic Pharmaceuticals (Alembic Pharma) is involved in manufacturing and marketing of India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities.
